In fact, anti-CD19 CAR T-cell therapy has become the preferred option for high-risk DLBCL, specifically those with primary refractory disease or relapse within 12 months of the first-line treatment [9]. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.